Business

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

Financial Post · September 15, 2026 at 6:01 a.m.

TORONTO -- QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS).

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

More from Financial Post

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

More in Business

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

William Watson: In new pamphlet, U.K.’s Kemi Badenoch points the (right) way

Pipeline, major projects shows Ottawa’s commitment to Alberta, Smith says